Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04128046 · ClinicalTrials.gov registry record · NA
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
A NA study, sponsored by New York Medical College.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04128046: Completed NA study, sponsored by New York Medical College.
NCT04128046 is a NA study that has completed, run by New York Medical College. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04128046, a NA study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Platelet-rich fibrin matrix (PRFM) is made from platelets that are extracted from a patient's blood, and many plastic surgeons and dermatologists have used it to fill in wrinkles and lines on the face. Both patients and doctors have observed that it gives extra volume in these areas and improves overall appearance. However, there is no research that shows how PRFM affects skin quality, such as pores, spots, red areas, and texture. The aim of this study is to determine whether PRFM has a role in rejuvenating facial skin.
Primary Outcome
Difference between pre- and post-treatment VISIA analysis scores for skin parameters of spots, wrinkles, texture, and pores
Interventions
- PROCEDURE Saline injection
- PROCEDURE PRFM injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-03 |
| Est. Completion | 2019-06-01 |
| Phase | NA |
What the finished NCT04128046 record still lists
NCT04128046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline injection is the first listed.
NCT04128046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04128046 about?
NCT04128046 is a clinical study titled "The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation". Platelet-rich fibrin matrix (PRFM) is made from platelets that are extracted from a patient's blood, and many plastic surgeons and dermatologists have used it to fill in wrinkles and lines on the face. Both patients and doctors have observed that it gives extra volume in these areas and improves ove...
What is the current status of trial NCT04128046?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-03. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT04128046?
The interventions under investigation include: Saline injection (PROCEDURE), PRFM injection (PROCEDURE).
Who is sponsoring clinical trial NCT04128046?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04128046's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI